Current Neuro-Oncology
Volume
28 Number 8
20 March 2026
Home > Publications > Current Neuro-Oncology > Volume 28, Year 2026 > Number 8, 20 March
Bao Z, Xue Y, Liu Y, Li S, Wang L, Qu Y, Mou Y, Yu R, Wu J, Yao Y,
Shu K, Hu G, Cai L, Li W, Qiu X, Li Y, Zhang L, Qi S, Ji Y, Ma C,
Ma W, Li G, Tao R, Sun C, Chen L, Lv SQ, Liang P, Pan H, Peter
WYM, Danny CTM, Mao Q, Wei X, Jiang T.
Vebreltinib
for Previously Treated Astrocytoma, IDH-Mutant,
Grade 4, and Glioblastoma, IDH
Wild-Type with PTPRZ1-MET
Fusion Gene: A Multicenter, Phase III Randomized, Open-Label
Trial.
Cancer
Commun (Lond). 2026 Mar 11;46:0019. doi:
10.34133/cancomm.0019. PMID:
41821581. Trial
registration ID:
CTR20181664. ˍ
Haj Mohammad SF, Spiekman IAC, Verkerk K, Verbeek FAJ, Timmer H,
van Maren MA, Zeverijn LJ, Geurts BS, Daletzakis A, Roepman P,
Jansen AML, de Leng WWJ, Maas SLN, de Vos FYFL, Verheul HMW, Voest
EE, Gelderblom H.
BRAFV600E-mutated
central nervous system tumors benefit from treatment with
dabrafenib plus trametinib: Results from the Drug Rediscovery
Protocol.
Eur
J Cancer. 2026 Mar 11;238:116674. doi:
10.1016/j.ejca.2026.116674. PMID:
41830662. ˍ
Nordentoft S, Guldager R, Pappot H, Mathiesen T, Tolver A, Piil K.
A Supportive Group Intervention for
Caregivers to Patients Diagnosed With Glioblastoma: Protocol for
the SUGRI Study.
JMIR
Res Protoc. 2026 Mar 11;15:e81948. doi:
10.2196/81948. PMID:
41812182. Trial
registration ID: NCT06869577. ˍ
Orduña P, Cansanay RD, Erker C, Ratterman E, Schlosser MP,
Ronsley R, Cacciotti C, Cheng S, Hukin J, Aguilera D, Mazewski C,
Magimairajan V, Pillay-Smiley N, Sait SF, Cluster A, Abdelbaki MS,
Margol AS, Michaiel G, Chi S, Salloum R, Harrod V, Hoffman L,
Bracher A, Senapati A, Ramaswamy V, Zapotocky M, Lopez VS, Doris
K, Mynarek M, Rutkowski S, Lassaletta A, Bouffet E, Lafay-Cousin
L.
Group 4 Medulloblastomas of Early
Childhood Treated With High-Dose Chemotherapy- and Craniospinal
Irradiation-Sparing Approach.
Pediatr
Blood Cancer. 2026 Mar 13;73(5):e70181. doi:
10.1002/1545-5017.70181. PMID:
41823174˰ ˍ
Rubio-San-Simón A, Marshall LV, Karamouza E, André
N, Abbou S, Rubino J, Nebchi S, Aerts I, Thebaud E, Brisset C,
Ducassou S, Le Teuff G, Geoerger B.
Phase
I/II Study of the CDK2/9 Inhibitor Fadraciclib in Combination with
Chemotherapy in Children with Advanced Malignancies: Arm K of the
AcSé-ESMART Trial.
Target
Oncol. 2026 Mar 16;21(2):199-211. doi:
10.1007/s11523-026-01208-1. PMID:
41838385. Trial
registration ID: NCT02813135. ˍ
Yu Y, Hou X, Xu K.
A multi-database
pharmacovigilance study reveals distinctive immunosuppressive and
opportunistic infection disproportionality signals with
bevacizumab and temozolomide combination therapy in glioblastoma.
Front
Med (Lausanne). 2026 Mar 11;13:1773599. doi:
10.3389/fmed.2026.1773599. PMID:
41889512. ˍ
Pulsipher AM, Khattar G, Gotway MB, Grill MF, Knox MG, Limper AH,
Cartin-Ceba R, Vikram HR, Ham K.
Pneumocystis
jirovecii pneumonia in patients with CNS tumors receiving
dexamethasone: clinical outcomes and prophylaxis gaps.
J
Neurooncol. 2026 Mar 13;177(1):51. doi:
10.1007/s11060-026-05516-4. PMID:
41824164˰ ˍ
Dişel U, Kato S, Shreenivas A, Danyeli AE, Ahluwalia MS,
Kurzrock R.
Lessons from Exceptional
Responders with High-Grade Brain Tumors Treated with Precision
Targeted Therapies.
J
Immunother Precis Oncol. 2026 Mar 16;9(1):25-31. doi:
10.36401/JIPO-25-34. PMID:
41868199. ˍ
Chanoch-Myers R, Hara T, Greenwald
AC, Hoefflin R, Bussema L, Weisman HR, Nieblas-Bedolla E,
Gurramkonda J, Bekezhankyzy Z, Jucht A, Calvo Fernández E,
Spitzer A, Fung JMH, Chiara B, Al-Holou WN, Camelo-Piragua S,
Behnan J, Galli R, Wakimoto H, Suvà ML, Tirosh I.
A
blueprint for local and distal invasion programs in glioblastoma.
Nat
Commun. 2026 Mar
17;17(1):4079. doi:
10.1038/s41467-026-70470-8. PMID:
41844611. ˍ
Brown MH, Cherng HR, Assif JW, Sun
K, Mishra MV.
Conditional
Survival Estimates for Malignant Glioma Patients: Secondary
Analysis of RTOG 9006.
Am
J Clin Oncol.
2026 Mar 19;49(6):264-267. doi:
10.1097/COC.0000000000001296. PMID:
41850328˰ ˍ